Key result
Coronary artery disease, dyslipidemia, and TPO-RAs treatment (OR 4.591; 95% CI 1.238-17.023) were independent risk factors for thrombosis in patients with ITP.
Why the study?
ITP is not only a bleeding disease but also a potential thrombotic disease.
What are the independent risk factors for thrombosis in patients with ITP?
Observational (n=322)
What are the independent risk factors for thrombosis in patients with ITP?
Odds Ratio: 4.591 (95% CI 1.238–17.023)
p-value: p=0.023
Coronary artery disease, dyslipidemia, and TPO-RAs treatment are independent risk factors for thrombotic events in patients with ITP.
Thrombosis risk in ITP, especially chronic, warrants awareness; leaves open predictors and prevention strategies.
Objectives ITP is not only a bleeding disease but also a potential thrombotic disease.Methods This retrospective study analyzed the factors associated with the occurrence of thrombosis events in ITP patients.Results The overall incidence of thrombosis was 4.66% (15/322), with the incidence of arterial events was 2.17% (7/322) and of venous thrombosis was 2.80% (9/322). Thrombosis can occur in all stages and was more common in patients with chronic ITP (66.7%). In univariate logistic analysis, age (OR = 1.037, 95%CI (1.003,1.072), p = 0.032), hypertension (OR = 3.389, 95%CI (1.184,9.699), p = 0.023), coronary artery disease (OR = 10.714, 95%CI (2.462,46.619), p = 0.002), dyslipidemia (OR = 4.325, 95%CI (1.463,12.788), p = 0.008), and treatment with TPO-RAs (OR = 5.233, 95%CI (1.448,18.918), p = 0.012) were related to increased risk thrombotic events. In multivariate logistic analysis, results showed that coronary artery disease (OR = 9.486, 95% CI (1.858, 48.42), p = 0.007), dyslipidemia (OR = 3.983, 95% CI (1.255, 12.641), p = 0.019), as well as TPO-RAs treatment (OR = 4.591, 95% CI (1.238, 17.023), p = 0.023), were independent risk factors for thrombosis in ITP patients (p < 0.05).Conclusions Thrombotic events can occur at all stages of ITP with a higher percentage in chronic ITP. Coronary artery disease, dyslipidemia and TPO-RAs treatment are independent risk factors related to thrombosis in ITP patients.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted an observational in Immune thrombocytopenia (ITP) (n=322). TPO-RAs treatment vs. No TPO-RAs treatment was evaluated on Thrombosis (OR 4.591, 95% CI 1.238-17.023, p=0.023). Coronary artery disease, dyslipidemia, and TPO-RAs treatment (OR 4.591; 95% CI 1.238-17.023) were independent risk factors for thrombosis in patients with ITP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: